TransMedics Group Q3 2026 Earnings Date & Estimates

TransMedics Group (NASDAQ:TMDX) is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation. In addition to its medical devices, TransMedics provides related services, including organ procurement, preservation, transportation and transplant support through its National OCS Program. These services are intended to help transplant centers manage the logistics of retrieving and delivering donor organs.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets. The company was founded by Waleed H. Hassanein, who serves as its president and chief executive officer. TransMedics became a publicly traded company on the Nasdaq under the symbol TMDX in 2019.